Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EF9I
|
|||
| Former ID |
DIB014798
|
|||
| Drug Name |
A-76895
|
|||
| Synonyms |
IDDB2395
Click to Show/Hide
|
|||
| Indication | Epilepsy [ICD-11: 8A60-8A68] | Terminated | [1] | |
| Company |
Abbott Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium channel unspecific (NaC) | Target Info | Modulator | [2] |
| KEGG Pathway | Dopaminergic synapse | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002237) | |||
| REF 2 | CA patent application no. 849505, Sodium channel blockers reduce glucagon secretion. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.